Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results

被引：0
|
作者：
Michalaki, V. [1 ]
Gennatas, S. [1 ]
Gennatas, C. [1 ]
机构：
[1] Univ Athens, Arete Hosp, Oncol Clin, Athens, Greece
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70946-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：276 / 276
页数：1
相关论文
共 50 条
  • [1] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    [J]. ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [3] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    [J]. ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [4] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [5] Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
    Ciardiello, F.
    Troiani, T.
    Caputo, F.
    De Laurentiis, M.
    Tortora, G.
    Palmieri, G.
    De Vita, F.
    Diadema, M. R.
    Orditura, M.
    Colantuoni, G.
    Gridelli, C.
    Catalano, G.
    De Placido, S.
    Bianco, A. R.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1604 - 1609
  • [6] Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
    F Ciardiello
    T Troiani
    F Caputo
    M De Laurentiis
    G Tortora
    G Palmieri
    F De Vita
    M R Diadema
    M Orditura
    G Colantuoni
    C Gridelli
    G Catalano
    S De Placido
    A R Bianco
    [J]. British Journal of Cancer, 2006, 94 : 1604 - 1609
  • [7] Phase II study of the combination of docetaxel, capecitabine and carboplatinum as first line therapy in metastatic breast cancer (MBC)
    Mokaddem, Walid
    Kattan, Joseph
    Chahine, Georges
    Nasr, Fadi
    Farhat, Fadi
    Tueni, Elias
    Dagher, Joya
    Younes, Fariha
    Ghosen, Marwan
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 45 - 46
  • [8] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    [J]. EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
  • [9] Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer:: phase II results
    Tripathy, D.
    Moisa, C.
    Gluck, S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S226 - S226
  • [10] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345